Functional Imaging And Proteomics Techniques Predict Sensitivity To Chemoradiotherapy In Non-Small Cell Lung Cancer

Partâ… .18F-FDG PET/CT Early Predicts Sensitivity to Chemoradiotherapy in Non-Small Cell Lung cancerObjective This study aimed to investigate whether standard uptake values (SUVs) and metabolic tumor volume (MTV) measured from [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) predicts short-term outcome to radiotherapy with or without chemotherapy in patients with non-small cell lung cancer. Methods A total of 37 patients were included in study prospectively. All Patients were studied by FDG-PET before and after 40Gy RT with or without the two cycles of chemotherapy with a cisplatin-based regimen. The maximum and mean value of standard uptake value (SUVmax/SUVmean) and metabolism tumor volume (MTV) were used for semiquantitative assessment. Short-term outcome was assessed using the treatment response evaluation by the Response Evaluation Criteria in Solid Tumors. To determine the diagnostic accuracy of 18F-FDG PET in identifying responders, receiver-operating-characteristic (ROC) curve analysis was used. Results Changes in SUVmax, SUVmean and MTV were significantly more pronounced in responders than in nonresponders (P=0.002,0.002, 0.000). The thresholds of SUVmax, SUVmean and MTV determined by (ROC) curve analysis were 35.2%,41.7% and 42.0%. The specificity, sensitivity and veracity value of SUVmax, SUVmean and MTV predicting tumor response were 83.3%, 84.6% and 84.9%,79.2%,100% and 88.8%,70.8%,100% and 92.3%, respectively.Conclusions 18F-FDG PET/CT differentiates responders from nonresponders early in the course of therapy. This may help improve patient management by avoiding ineffective chemoradiotherapy and supporting the decision to continue the primary treatment in responding patients.Partâ…¡. Screening serum biomarkers for non-small cell lung cancer with different chemoradiotherapy sensitivity by serum proteomics techniquesObjective To find potential molecular targets for NSCLC diagnosis by comparing and analyzing differential proteins in serum between NSCLC patients with different chemoradiotherapy sensitivity, providing evidence for the early diagnosis of NSCLC. Methods The protein in serum were separated by two-dimensional gel electrophoresis (2-DE) after the high abundance proteins were removed from serum. The significantly differentially expressed proteins were analyzed by liquid chromatography and tendem mass spectrometry (LC MS/MS). Results Protein in serum of each case was successfully separated on 2D gels. Among eight differently expressed protein, six differentially expressed proteins were successfully identified among which five proteins had over expression and one proteins had weak expression in patients with resistive tumor. Conclusion There were Significant discrepancies in serum protein expression between NSCLC patients with different chemoradiotherapy sensitivity. And some of the differentially expressed proteins found by the proteomic approach may be potential molecular targets for personalizing the treatment of NSCLC.